Key Highlights
- The Nephrotic Syndrome market is projected to witness consistent growth throughout the forecast period (2023-2034). The market size of Nephrotic Syndrome in the 7MM is expected to increase, driven by the launch of emerging therapies.
- The analyst's analyst projects that among the total diagnosed prevalent cases of Nephrotic Syndrome in 7MM approximately 34% of cases were from the US. As per our estimations, in 2022, the EU4 and the UK accounted for nearly 367 thousand diagnosed prevalent cases of Nephrotic Syndrome.
- In the 7MM, the market mainly consisted of corticosteroids, calcineurin inhibitors, ACE Inhibitors/ARB, immunosuppressant’s, and others which generated nearly USD 401 million in 2022.
- The total market size of the Nephrotic Syndrome treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, Atacicept, Atrasentan, Gazyva/Gazyvaro (obinutuzumab), Zigakibart (BION-1301), and others.
The Nephrotic Syndrome market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Nephrotic Syndrome market size from 2020 to 2034. The report also covers current Nephrotic Syndrome treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2020-2034
Disease Understanding and Treatment Algorithm
Nephrotic Syndrome Overview
Nephrotic syndrome is a clinical syndrome defined by massive proteinuria responsible for hypoalbuminemia, with resulting hyperlipidemia, edema, and various complications. Nephrotic syndrome may stem from diverse underlying factors, encompassing conditions like minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, lupus nephritis, diabetic nephropathy, infections, genetic disorders, specific medications, and more. Prolonged nephrotic syndrome can result in complications such as infections, malnutrition, and an elevated risk of cardiovascular disease. Consequently, accurately pinpointing the precise cause is imperative for effective treatment and comprehensive management.From a pathological standpoint, nephrotic syndrome entails changes in the structure and function of the glomeruli, which are the small filtration units in the kidneys tasked with eliminating waste and surplus fluids from the blood. The key characteristics of nephrotic syndrome involve heightened permeability of the glomerular filtration barrier, leading to the excretion of proteins, notably albumin, in the urine.
Nephrotic Syndrome Diagnosis
The diagnostic process for nephrotic syndrome encompasses a clinical assessment, blood examinations to evaluate serum albumin and lipid concentrations, urine analyses to detect proteinuria and imaging modalities such as ultrasound. Additionally, a kidney biopsy may be undertaken to pinpoint the root cause, aiding in informed treatment choices. This comprehensive approach ensures a thorough understanding of the condition's nuances, facilitating precise diagnosis and tailored interventions.Nephrotic Syndrome Treatment
The treatment of nephrotic syndrome involves addressing the fundamental cause and implementing measures to mitigate elevated blood pressure, elevated cholesterol levels, edema, and infection susceptibility. Therapeutic interventions typically comprise medications and dietary modifications. Certain antihypertensive drugs, specifically ACE inhibitors and ARBs, exhibit the potential to decelerate kidney diseases associated with nephrotic syndrome.Nephrotic Syndrome Epidemiology
As the market is derived using the patient-based model, the Nephrotic Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Nephrotic Syndrome and Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.As per the analyst's estimations, the total diagnosed prevalent cases of Nephrotic Syndrome in the 7MM were approximately 786 thousand in 2022 and are projected to increase during the forecast period.
- The overall count of individuals diagnosed with Nephrotic Syndrome in the United States was approximately 268 thousand in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
- Among the 7MM, the US accounted for nearly 214 thousand cases of Primary Glomerulonephropathies, and 54 thousand cases of Secondary Glomerulonephropathies. These cases are expected to increase during the forecast period (2023-2034).
- Among EU4 and the UK, Germany had the highest diagnosed prevalent population of Nephrotic Syndrome, with about 98 thousand cases, followed by the UK and France in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
- In Japan, there were around 151 thousand diagnosed prevalent cases of Nephrotic Syndrome in 2022. These cases are expected to decrease by 2034.
Nephrotic Syndrome Drug Chapters
The drug chapter segment of the Nephrotic Syndrome report encloses a detailed analysis of Nephrotic Syndrome marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Nephrotic Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.Emerging Drugs
Atacicept: Vera Therapeutics
Atacicept developed by Vera Therapeutics, is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgA nephropathy and lupus nephritis.Atrasentan: Chinook Therapeutics/ Novartis
Atrasentan is an oral potent and selective endothelin A (ETA) receptor antagonist, which works by inhibiting the ETA receptor activation of multiple renal cell types. This blockade reduces kidney inflammation and fibrosis, thus leading to reduced proteinuria in patients with chronic kidney disease.Nephrotic Syndrome Market Outlook
Nephrotic syndrome is a collection of symptoms that signal impaired kidney function. These symptoms encompass proteinuria, hypoalbuminemia, edema, hyperlipidemia, and various other associated complications.The management of nephrotic syndrome entails addressing underlying medical conditions contributing to its onset. Healthcare professionals may prescribe medications and dietary modifications to regulate symptoms and address complications associated with nephrotic syndrome. Currently, there are no authorized therapies specifically designed for treating nephrotic syndrome, and the predominant treatment strategies often involve off-label approaches. Corticosteroids like prednisone, cyclophosphamide, and cyclosporine are employed to induce remission in nephrotic syndrome. Diuretics are utilized to alleviate edema, while angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers are employed to diminish proteinuria.
Progress in the treatment of nephrotic syndrome has transformed patient care, integrating lifestyle modifications, medications, and procedures. Emerging therapies, including monoclonal antibodies and antagonists targeting APRIL and BAFF, among others, hold the potential for improving patient outcomes. Continuous research and ongoing clinical trials are shaping a promising future for nephrotic syndrome treatment, providing optimism for a world with decreased morbidity and mortality.
The market for Nephrotic Syndrome is expected to experience positive growth with the approval of potential drugs like Atacicept, Atrasentan, Gazyva/Gazyvaro (obinutuzumab), Zigakibart (BION-1301), and others.
- The Nephrotic Syndrome market’s total size in the 7MM reached approximately USD 401 million in 2022. Projections indicate a substantial growth during the forecast period.
- Out of the 7MM, the United States dominated the market in 2022, representing the largest share at nearly 50%.
- In 2022, EU4 and the UK captured an estimated USD 137 million, which is anticipated to increase at a substantial CAGR. Among the European countries, Germany covered the largest market share in 2022, followed by the UK, France, and Italy. Spain accounted for the least market in the same year.
- Japan alone represented approximately 16% of the total Nephrotic Syndrome market in 2022, projected to increase at a substantial CAGR during the study period.
- The total market size of the Nephrotic Syndrome treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.
Nephrotic Syndrome Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, Atacicept in the US is expected to be launched by 2027.Nephrotic Syndrome Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Nephrotic Syndrome emerging therapies.KOL Views
To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Nephrotic Syndrome evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Boston Children’s Hospital, Ohio State University, Montefiore Medical Center, Hannover Medical School, Hannover, Hôpital Robert-Debré, APHP, Paris, Istituto G. Gaslini, Genoa, Hospital Universitario Fundación Jiménez Díaz, UCL Department of Renal Medicine, National Health Service, England, Fukushima Medical University, Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Japan, and others.The analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Nephrotic Syndrome market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report
- The report covers a segment of key events, an executive summary, descriptive overview of Nephrotic Syndrome, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
- Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
- A detailed review of the Nephrotic Syndrome market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Nephrotic Syndrome market.
Nephrotic Syndrome Report Insights
- Patient Population
- Therapeutic Approaches
- Nephrotic Syndrome Pipeline Analysis
- Nephrotic Syndrome Market Size and Trends
- Existing and Future Market Opportunity
Nephrotic Syndrome Report Key Strengths
- 12 years Forecast
- The 7MM Coverage
- Nephrotic Syndrome Epidemiology Segmentation
- Key Cross Competition
- Conjoint Analysis
- Drugs Uptake and Key Market Forecast Assumptions
Nephrotic Syndrome Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint Analysis)
Key Questions
Market Insights
- What was the Nephrotic Syndrome total market size, the market size by therapies, and market share (%) distribution in 2020, and how would it all look in 2034? What are the contributing factors for this growth?
- What unmet needs are associated with the current treatment market of Nephrotic Syndrome?
- What are the patents of emerging therapies for Nephrotic Syndrome?
- Which drug is going to be the largest contributor by 2034?
- What are the pricing variations among different geographies for approved and off-label therapies?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights
- What are the disease risks, burdens, and unmet needs of Nephrotic Syndrome? What will be the growth opportunities across the 7MM concerning the patient population of Nephrotic Syndrome?
- What is the historical and forecasted Nephrotic Syndrome patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
- Why do only limited patients appear for diagnosis?
- Which country is more prevalent for Nephrotic Syndrome and why?
- What factors are affecting the diagnosis of the indication?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
- What are the current options for treating Nephrotic Syndrome? What are the current guidelines for treating Nephrotic Syndrome in the US and Europe?
- How many companies are developing therapies for treating Nephrotic Syndrome?
- How many emerging therapies are in the mid-stage and late stage of development for treating Nephrotic Syndrome?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
- What are the key designations that have been granted for the emerging therapies for Nephrotic Syndrome?
- Patient acceptability in terms of preferred treatment options as per real-world scenarios?
- What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
- What are the 7MM historical and forecasted markets of Nephrotic Syndrome?
Reasons to Buy
- The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Nephrotic Syndrome Market.
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
- Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
- Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
- To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
Frequently Asked Questions
1. What is the forecast period covered in the report?
The Nephrotic Syndrome Epidemiology and Market Insight report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of market dynamics and trends during this timeframe.2. Who are the key players in the Nephrotic Syndrome market?
The Nephrotic Syndrome emerging market many drugs. The major key players developing therapies for Nephrotic Syndrome are Vera Therapeutics, Novartis, Chinook Therapeutics, AstraZeneca, Hoffmann-La Roche, Otsuka Pharmaceutical Development and Commercialization, Visterra and others.3. How is the market size estimated in the forecast report?
The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as prevalent cases, treatment costs, revenue generated, and market trends.4. What is the key driver of the Nephrotic Syndrome market?
The increase in diagnosed prevalent cases of Nephrotic Syndrome and the launch of emerging therapies are attributed to be the key drivers for increasing Nephrotic Syndrome market.5. What is the expected impact of emerging therapies or advancements in Nephrotic Syndrome treatment on the market?
Introducing new therapies, advancements in disease understanding and diagnostic techniques, and innovations in treatment approaches can significantly impact the Nephrotic Syndrome treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.6. Does the report provide insights into the competitive landscape of the market?
The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Nephrotic Syndrome market.Table of Contents
Executive Summary
Country Wise-Acute Respiratory Distress Syndrome (ARDS) Epidemiology
The epidemiology segment also provides the Acute Respiratory Distress Syndrome (ARDS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Acute Respiratory Distress Syndrome (ARDS) Drug Chapters
The drug chapter segment of the Acute Respiratory Distress Syndrome (ARDS) report encloses the detailed analysis of Acute Respiratory Distress Syndrome (ARDS) marketed drugs and mid- and late-stage pipeline drugs. It also helps to understand the Acute Respiratory Distress Syndrome (ARDS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Acute Respiratory Distress Syndrome (ARDS) Emerging Drugs
Traumakine: Faron Pharmaceuticals
Interferon-beta-1a - also known as Traumakine; FP-1201-lyo; MR11A8; FP-1201; Recombinant Human IFN Beta-1a - is under development by Faron Pharmaceuticals as its lead drug candidate. It is a lyophilized powder form of recombinant human IFN beta-1a reconstituted in water for injection. It is administered intravenously, and targets the Interferon-beta receptor 1, activating its action. In January 2018, Faron Pharmaceuticals received Fast Track designation from the US Food and Drug Administration (FDA) for Traumakine, for the treatment of ARDS. The drug is in phase III (CALIBER Global Study) clinical developmental trial for the patients with ARDS.
BIO-11006: BioMarck Pharmaceuticals
BioMarck Pharmaceuticals is developing its lead compound BIO-11006 under the Phase II stage of development for the treatment of Adult Respiratory Distress Syndrome (ARDS). Biomarck's BIO-11006 is a novel, highly soluble, patented, 10 amino acid peptides. It acts as a MARCKS (Myristoylated alanine-rich C kinase substrate) protein inhibitor and is being developed to specifically target the MARCKS protein to inhibit cancer cell division and movement. Furthermore, it is a water-soluble, stable aerosolized anti-MARCKS peptide inhalation solution that involves aerosolized delivery of either the active drug or placebo by the “Aeroneb Pro nebulizer.”
MultiStem: Athersys
MultiStem - also known as AMI MultiStem; HLCM 051 and PF-05285401 - is a patented regenerative product which can promote tissue repair and healing in a variety of ways, such as through the production of multiple therapeutic factors produced in response to signals of inflammation and tissue damage and restore immune system balance. MultiStem is under development by Athersys and is currently in the Phase II stage for the treatment of Acute Respiratory Distress Syndrome. Currently, the US FDA granted Fast Track designation to Athersys for its clinical program evaluating MultiStem cell therapy for the treatment of ARDS.
Solnatide: Apeptico Forschung und Entwicklung GmbH
Solnatide (AP301; synonym to TNF-derived TIP-peptide) under development by Apeptico Forschung und Entwicklung GmbH is a synthetic molecule whose structure bases on the lectin-like domain of the Human Tumor Necrosis Factor α. The AP301 peptide is water-soluble and can be administered into the lung by oral inhalation. The drug is conducting phase II clinical developmental trial in patients with ARDS.
Apart from these, Lenzilumab, tocilizumab (TCZ), aviptadil, ruxolitinib, tradipitant, and remestemcel-L, are the other pipeline therapies, which are expected to enter the market in the forecasted period that will be targeting the COVID-19 associated ARDS cases.
Lenzilumab: Humanigen, Inc.
Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody drug candidate that is being evaluated in an ongoing Phase III trial and was selected by the National Institutes of Health for its COVID-19 Big Effect Trial.
Actemra/RoActemra (Tocilizumab): Roche Pharma AG
Actemra/RoActemra (Tocilizumab) is another investigational molecule that is in phase III stage of development for SARS-CoV-2 infection and evidence of systemic inflammation. From some studies, it has been observed that Tocilizumab can be a suitable and effective therapy for severe cases of COVID-19 associated with acute respiratory distress syndrome.
Acute Respiratory Distress Syndrome (ARDS) Market Outlook
Despite recent advances in critical care, the mortality due to ARDS varies from 35% to 45% in various studies. The mortality has been reported to be associated with organ failure, sepsis, age, and associated comorbid illness. The treatment of ARDS involves general supportive measures, ventilator strategies, and appropriate treatment of the underlying condition. Besides general supportive measures, pharmacological interventions are commonly considered throughout ARDS. Although research involving the investigation of drug candidates is being carried out for over a decade, only a few pharmacological therapies have emerged for ARDS. In the off-label treatment options, STATIN therapy, NMBAs, and glucocorticosteroids are recommended because there is no approved therapy for this indication yet.
The Acute Respiratory Distress Syndrome (ARDS) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Acute Respiratory Distress Syndrome (ARDS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Acute Respiratory Distress Syndrome (ARDS) market trend of each late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, Acute Respiratory Distress Syndrome (ARDS) 7MM market is expected to change in the study period 2017-2030.
Key Findings
This section includes a glimpse of the Acute Respiratory Distress Syndrome (ARDS) 7MM market.
- According to the publisher estimates, the United States accounts for the largest market size of Acute Respiratory Distress Syndrome (ARDS), in comparison to Japan and EU5 (Germany, Italy, France, UK and Spain).
- The market size of Acute Respiratory Distress Syndrome (ARDS) in the seven major markets was 917.81 Million in 2017.
- Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of ARDS and awareness of the disease.
The United States Market Outlook
This section provides the total Acute Respiratory Distress Syndrome (ARDS) market size and market size by therapies in the United States.
EU-5 Market Outlook
The total Acute Respiratory Distress Syndrome (ARDS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Acute Respiratory Distress Syndrome (ARDS) market size and market size by therapies in Japan are provided.
Acute Respiratory Distress Syndrome (ARDS) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Acute Respiratory Distress Syndrome (ARDS) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Acute Respiratory Distress Syndrome (ARDS) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Acute Respiratory Distress Syndrome (ARDS) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Acute Respiratory Distress Syndrome (ARDS) emerging therapies.
Competitive Intelligence Analysis
The publisher performs competitive and market intelligence analysis of the Acute Respiratory Distress Syndrome (ARDS) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Acute Respiratory Distress Syndrome (ARDS), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
- Comprehensive insight has been provided into the Acute Respiratory Distress Syndrome (ARDS) epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Acute Respiratory Distress Syndrome (ARDS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of Acute Respiratory Distress Syndrome (ARDS) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Acute Respiratory Distress Syndrome (ARDS) market.
Report Highlights
- Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is anticipated to rise in the forecasted period (2017-2030).
- The market for ARDS in the 7MM is projected to rise during the study period (2017-2030).
- Dynamic research and developmental activity with 60+ companies in the pipeline at different stages.
- In the coming years, Acute Respiratory Distress Syndrome (ARDS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Acute Respiratory Distress Syndrome (ARDS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Acute Respiratory Distress Syndrome (ARDS). Launch of emerging therapies will significantly impact the Acute Respiratory Distress Syndrome (ARDS) market.
- The in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Acute Respiratory Distress Syndrome (ARDS) Report Insights
- Patient Population
- Therapeutic Approaches
- Acute Respiratory Distress Syndrome (ARDS) Pipeline Analysis
- Acute Respiratory Distress Syndrome (ARDS) Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Acute Respiratory Distress Syndrome (ARDS) Report Key Strengths
- Eleven Years Forecast
- 7MM Coverage
- Acute Respiratory Distress Syndrome (ARDS) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Acute Respiratory Distress Syndrome (ARDS) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Acute Respiratory Distress Syndrome (ARDS) market share (%) distribution in 2017 and how it would look like in 2030?
- What would be the Acute Respiratory Distress Syndrome (ARDS) total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Acute Respiratory Distress Syndrome (ARDS) market size during the forecast period (2020-2030)?
- At what CAGR, the Acute Respiratory Distress Syndrome (ARDS) market is expected to grow at the 7MM level during the forecast period (2020-2030)?
- What would be the Acute Respiratory Distress Syndrome (ARDS) market outlook across the 7MM during the forecast period (2020-2030)?
- What would be the Acute Respiratory Distress Syndrome (ARDS) market growth till 2030, and what will be the resultant market size in the year 2030?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden and unmet needs of Acute Respiratory Distress Syndrome (ARDS)?
- What is the historical Acute Respiratory Distress Syndrome (ARDS) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of Acute Respiratory Distress Syndrome (ARDS) at the 7MM level?
- What will be the growth opportunities across the 7MM for the patient population pertaining to ARDS?
- Out of the countries mentioned above, which country would have the highest prevalent population of Acute Respiratory Distress Syndrome (ARDS) during the forecast period (2020-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the treatment of Acute Respiratory Distress Syndrome (ARDS) along with the approved therapy?
- What are the current treatment guidelines for the treatment of Acute Respiratory Distress Syndrome (ARDS) in the US and Europe?
- What are the Acute Respiratory Distress Syndrome (ARDS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
- How many therapies are developed by each company for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
- How many emerging therapies are in the mid-stage and late-stage of development for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Respiratory Distress Syndrome (ARDS) therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute Respiratory Distress Syndrome (ARDS) and their status?
- What are the key designations that have been granted for the emerging therapies for Acute Respiratory Distress Syndrome (ARDS)?
- What are the 7MM historical and forecasted market of Acute Respiratory Distress Syndrome (ARDS)?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the Acute Respiratory Distress Syndrome (ARDS).
- To understand the future market competition in the ARDS market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Acute Respiratory Distress Syndrome (ARDS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for Acute Respiratory Distress Syndrome (ARDS) market.
- To understand the future market competition in the Acute Respiratory Distress Syndrome (ARDS) market.
List of Companies
- Faron Pharmaceuticals
- PhaseBio Pharmaceuticals
- Sage Therapeutics
- Chimerix
- Direct Biologics
- Kiniksa Pharmaceuticals
- Pluristem Therapeutics
- Alexion Pharmaceuticals
- Biomarck Pharmaceuticals
- Athersys
- Veru
- Apeptico Forschung und Entwicklung GmbH
- Alexion Pharmaceuticals
- Humanigen, Inc.
- Roche Pharma AG
- Alexion
- Mylan Laboratories
- Vanda Pharmaceuticals Inc.; the University of Illinois at Chicago
- Laboratoire français de Fractionnement et de Biotechnologies
- Ache Laboratorios Farmaceuticos
- Implicit Bioscience
- Alexion
- NeuroRx/Relief Therapeutics
- CytoDyn
- Kiniksa
- Biohaven Pharmaceutical Holding Co. Ltd.
- Kinevant Sciences GmbH/Roivant Sciences
- Iltoo Pharma
- Eli Lilly and Company
- Merck/Eli Lilly
- Apeiron Biologics
- Roche AG
- aTyr Pharma
- Algernon Pharmaceuticals
- Histocell, S.L.
- Cellenkos Inc
- Celularity Inc.; Sorrento Therapeutics Inc.; Lung Biotechnology PBC, a subsidiary of United Therapeutics Corp.
- Hospital to Academy of Military Medical Sciences/Ivy Institute of Stem Cells Co. Ltd
- Lattice Biologics Ltd.
- Meridigen Biotech
- Theravance Biopharma,
- Mesoblast Limited
- Aqualung Therapeutics Corp.
- Diffusion Pharmaceuticals Inc.; University of Virginia
- Lamellar Biomedical Ltd.
- Leading Biosciences Inc.
- Mannkind Corp.; Immix Biopharma Inc.
- Medicinova Inc.
- Bioxytran Inc.
- Mallinckrodt plc
- GEn1E Lifesciences
- ZyVersa Therapeutics
- Quark Pharmaceuticals
- Navigen pharmaceuticals
- XORTX Therapeutics
- Tiziana
- Bioaegis Therapeutics Inc.
- Caladrius Biosciences Inc.
- Cyclacel Pharmaceuticals
- Mallinckrodt /Novoteris LLC
- Noveome Biotherapeutics
- Windtree Therapeutics
- Ampio Pharmaceuticals Inc.
- Cerecor Inc.
- Predictive Biotech, of Salt Lake City, a subsidiary of Predictive Technology Group
- Pharmazz
- Noxopharm Co.
- GlaxoSmithKline
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Veru
- Direct Biologics
- Athersys
- Healios
- MediciNova
